Integral Derivatives’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Integral Derivatives’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$1.32M	Sell	15,000 -39,700	-73%	-$3.62M	0.03%	184
2017 Q4	$4.64M	Buy	54,700 +4,600	+9%	+$385K	0.09%	133
2017 Q3	$4.34M	Buy	50,100 +19,800	+65%	+$1.59M	0.08%	157
2017 Q2	$2.34M	Sell	30,300 -57,000	-65%	-$4.04M	0.05%	272
2017 Q1	$6.05M	Sell	87,300 -28,700	-25%	-$1.93M	0.11%	106
2016 Q4	$6.87M	Buy	116,000 +100,700	+658%	+$6.22M	0.13%	99
2016 Q3	$1.01M	Buy	15,300 +1,800	+13%	+$111K	0.02%	432
2016 Q2	$730K	Sell	13,500 -34,000	-72%	-$1.86M	0.02%	499
2016 Q1	$2.45M	Sell	47,500 -2,500	-5%	-$130K	0.08%	180
2015 Q4	$3.5M	Sell	50,000 -45,600	-48%	-$3.11M	0.09%	178
2015 Q3	$5.95M	Sell	95,600 -26,500	-22%	-$2.09M	0.16%	91
2015 Q2	$10.3M	Buy	122,100 +83,400	+216%	+$6.49M	0.28%	58
2015 Q1	$2.91M	Buy	+38,700	New	+$2.7M	0.06%	193
2014 Q2	–	Sell	-4,500	Closed	-$214K	–	1542
2014 Q1	$214K	Buy	+4,500	New	+$230K	﹤0.01%	1167

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Integral Derivatives's XBI Position: Q1 2018 in Review

Integral Derivatives reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 72% in Q1 2018, selling an estimated $676K and leaving 2,917 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #549.

Integral Derivatives first reported a position in XBI in Q3 2015 and has held it in 8 quarters since. The position peaked at $876K in Q4 2017. 414 funds tracked by Wall St. Rank hold XBI as of Q1 2018.

Integral Derivatives held 2,917 shares of State Street SPDR S&P Biotech ETF worth $256K as of Q1 2018.
Integral Derivatives sold 7,400 State Street SPDR S&P Biotech ETF shares in Q1 2018, an estimated $676K.
State Street SPDR S&P Biotech ETF made up 0.01% of Integral Derivatives's portfolio in Q1 2018, its #549 holding.
Integral Derivatives first reported a position in State Street SPDR S&P Biotech ETF in Q3 2015 and has held it in 8 quarters since.
Integral Derivatives's State Street SPDR S&P Biotech ETF position peaked at $876K in Q4 2017.
414 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.